← 홈

Antibody

1,830개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-10 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 1,830개
AntibodystaleJanssen Research & Development,…Phase 2

Talacotuzumab (Talacotuzumab)

Myelodysplastic Syndromes · Myelodysplastic Syndromes

#MyelodysplasticSyndromes#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleGlaxoSmithKlinePreclinical

sunitinib, sorafenib, bevacizumab, and pazopanib (Targeted agents indicated in management of advanced/metastatic RCC, Targeted agents indicated in management of advanced/metastatic RCC (sunitinib, sorafenib, bevacizumab, and pazopanib))

Carcinoma, Renal Cell · Carcinoma, Renal Cell

#CarcinomaRenalCell#Antibody#Preclinical#항체#면역항체+4
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

trastuzumab (Herceptin, Targeted therapy based on molecular profiling : Lapatinib + Trastuzumab)

Reccurent/Metastatic Solid Tumor Disease · Reccurent/Metastatic Solid Tumor Disease

#ReccurentMetastaticSolidTumorDis#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

Targeted therapy with bevacizumab (Targeted therapy with bevacizumab)

Locally Advanced Rectal Cancer (LARC) · Locally Advanced Rectal Cancer (LARC)

#LocallyAdvancedRectalCancerLARC#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleFudan UniversityPhase 2

trastuzumab (Herceptin, Taxanes combined with trastuzumab and pertuzumab.)

Advanced HER2-positive Breast Cancer · HER2

#HER2#Antibody#Phase2#항체#면역항체+3
효능 ORR 91.8%임상시험 1상태 RECRUITING
AntibodystaleQamar KhanPhase 2

trastuzumab (Herceptin, Taxotere, Carboplatin, Herceptin + Pertuzumab)

HER2-positive Breast Cancer · HER2

#HER2#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleImmunocore LtdPhase 3

pembrolizumab (Keytruda, Tebentafusp with Pembrolizumab)

Advanced Melanoma · Advanced Melanoma

#AdvancedMelanoma#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleJanssenPhase 2

Teclistamab Monotherapy (Teclistamab Monotherapy)

Relapse Multiple Myeloma; Refractory Multiple Myeloma · FRα

#FR#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystaleJanssenPhase 2

FDA-approved (Teclistamab, Teclistamab(FDA-approved))

Multiple Myeloma; Cytokine Release Syndrome · FRα

#FR#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 DISCONTINUED
AntibodystaleChinese SLE Treatment And Resea…Approved

Telitacicept (Telitacicept)

ANCA Associated Vasculitis · Systemic Lupus Erythematosus (SLE)

#SystemicLupusErythematosusSLE#Antibody#Approved#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleXinqiao Hospital of ChongqingPhase 2

Thalidomide+cetuximab+FOLFOX/FOLFIRI (Thalidomide+cetuximab+FOLFOX/FOLFIRI)

Thalidomide Enhances Clinical Efficacy of Cetuximab Combined With Standard Chemotherapy for Left Colorectal Cancer · Thalidomide Enhances Clinical Efficacy o

#ThalidomideEnhancesClinicalEffic#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleRuijin HospitalPhase 2

Tirelizumab (Tirelizumab)

Esophageal Squamous Cell Carcinoma · Esophageal Squamous Cell Carcinoma

#EsophagealSquamousCellCarcinoma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleTianjin Medical University Canc…Phase 2

Tiselizumab (Tiselizumab)

Follicular Lymphoma · Follicular Lymphoma

#FollicularLymphoma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleBeiGenePhase 2

Tislelizumab Combined With Bevacizumab and Platinum Plus Pemetrexed (Tislelizumab Combined With Bevacizumab and Platinum Plus Pemetrexed)

Non-squamous Non-small Cell Lung Cancer; EGFR Gene Mutation · EGFR

#EGFR#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 ACTIVE
AntibodystaleBeiGenePhase 2

Tislelizumab combined with chemotherapy (Tislelizumab combined with chemotherapy)

Rectal Cancer; Rectal Cancer Stage II · Rectal Cancer

#RectalCancer#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleBeiGenePhase 2

Tislelizumab plus Bevacizumab (Tislelizumab plus Bevacizumab)

Astrocytoma of Brain · Astrocytoma of Brain

#AstrocytomaofBrain#Antibody#Phase2#항체#면역항체+2
효능 ORR 37.1%임상시험 1상태 RECRUITING
AntibodystaleBeiGenePhase 2

Tislelizumab+Bevacizumab+Oxaliplatin+Capecitabine (Tislelizumab+Bevacizumab+Oxaliplatin+Capecitabine)

Tislelizumab; Bevacizumab · Tislelizumab

#Tislelizumab#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleBeiGenePhase 3

Tislelizumab+Oxaliplatin+Capecitabine (Tislelizumab+Oxaliplatin+Capecitabine)

Gastric Carcinoma · Gastric Carcinoma

#GastricCarcinoma#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleBeiGenePhase 1

trastuzumab (Herceptin, Tislelizumab，atezolizumab or Trastuzumab)

Gastric Cancer · Gastric Cancer

#GastricCancer#Antibody#Phase1#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleChugai PharmaceuticalPhase 1

Tocilicumab (Tocilicumab)

Hepatocellular Carcinoma (HCC) · Hepatocellular Carcinoma (HCC)

#HepatocellularCarcinomaHCC#Antibody#Phase1#항체#면역항체+2
임상시험 1상태 RECRUITING

75 / 92 페이지

← 이전다음 →